In the recent past, a plethora of drugs have been approved for the treatment of multiple
sclerosis (MS). These therapeutics are mainly confined to immunomodulatory or …

In the past decades, multiple sclerosis (MS) treatment has experienced vast changes
resulting from major advances in disease-modifying therapies (DMT). Looking at the overall …

The treatment of multiple sclerosis (MS) remains challenging despite the great efforts made
in the development of novel therapies. Driven by the growing knowledge of the …

Background: Immune-mediated demyelination and consequent degeneration of
oligodendrocytes and axons are hallmark features of multiple sclerosis (MS). Remyelination …

The multiple sclerosis (MS) neurotherapeutic landscape is rapidly evolving. New disease-
modifying therapies (DMTs) with improved efficacy and safety, in addition to an expanding …

Multiple sclerosis (MS), an incurable but manageable disorder, is characterized by chronic
inflammatory demyelination and neurodegeneration in the central nervous system. Although …

In recent years, multiple sclerosis (MS) research has progressed on several fronts,
prompting numerous clinical trials, primarily for immunotherapeutics. Although several new …

The treatment of multiple sclerosis (MS), the most common chronic inflammatory,
demyelinating and neurodegenerative disease of the central nervous system (CNS) …

Introduction Immunotherapies for multiple sclerosis (MS) significantly decrease the risk of
new relapses. However, the chronic compartmentalized inflammation and …

Remyelination in the CNS is the natural process of damage repair in demyelinating
diseases such as multiple sclerosis (MS). However, remyelination becomes inadequate in …